



## NanoString Highlights Record Number of nCounter-Based Abstracts at the 2018 Annual Meeting of the American Society of Clinical Oncology

May 31, 2018

*More than 50 abstracts highlight the diverse capabilities of NanoString's technologies in immuno-oncology, biomarker development and validation, and cancer characterization*

SEATTLE, May 31, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted a record number of abstracts that will be presented at the American Society of Clinical Oncology (ASCO) conference being held June 1-5, 2018, in Chicago, Illinois.

"We're proud of the extensive body of nCounter™-enabled research that is being presented at this year's meeting of the American Society of Clinical Oncology," said Brad Gray, NanoString's president and CEO. "This includes important clinical applications of our products for current and potential diagnostic tests for immuno-oncology, breast cancer and lymphoma."

At least 53 abstracts using NanoString's technologies will be presented at ASCO, including applications of gene expression profiling in cancer and immuno-therapy using NanoString products like the PanCancer Panel family and IO 360™, as well as diagnostic applications such as subtyping breast cancer and lymphoma.

Below is a subset of abstracts that best illustrate the unique capabilities of NanoString's technology platforms to span the continuum from biomarker targeted discovery to clinical applications. A complete list of NanoString-enabled abstracts can be found in the table that follows.

### Immuno-oncology

Title: Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data

Date/Time: Monday, June 4, 2018, 3:00pm-4:30pm CT

Author: Marleen Kok, MD

Poster #/Location: 1012/Clinical Science Symposium, Hall D2

Hyperlink: <https://meetinglibrary.asco.org/record/160551/abstract>

Title: Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4

Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT

Author: Elisa A. Rozeman, MD

Poster #/Location: 9585/Board 412

Hyperlink: <https://meetinglibrary.asco.org/record/163660/abstract>

Title: Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1

Date/Time: Sunday, June 3, 2018, 8am-11:30am CT

Author: Edward B. Garon, MD

Poster #/Location: 9018/Board 341

Hyperlink: <https://meetinglibrary.asco.org/record/160279/abstract>

Title: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)

Date/Time: Monday, April 16 2018, 1pm-5:00pm CT

Author: Nizar M. Tannir, MD

Poster #/Location: 4509/Board 335

Hyperlink: <https://meetinglibrary.asco.org/record/161707/abstract>

Title: Immune profiling of BRCA-mutated breast cancers

Date/Time: Saturday, June 2, 2018, 8:00am-11:30am CT

Author: Jeremy Meyer Force, DO

Poster #/Location: 585/Board 77

Hyperlink: <https://meetinglibrary.asco.org/record/163391/abstract>

Title: Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

Date/Time: Saturday, June 2, 2018, 1:15pm-4:45pm CT

Author: Inge Tinhofer, PhD

Poster #/Location: 6047/Board 35

Hyperlink: <https://meetinglibrary.asco.org/record/162474/abstract>

Title: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody

Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT

Author: Sanjiv S. Agarwala, MD

Poster #/Location: 9530/Board 357

Hyperlink: <https://meetinglibrary.asco.org/record/163453/abstract>

Title: Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma

Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT

Author: Robert Hans Ingemar Andtbacka, MD

Poster #/Location: 9541/Board 368

Hyperlink: <https://meetinglibrary.asco.org/record/163701/abstract>

Title: Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide

Date/Time: Saturday, June 2, 2018, 8:00am-11:30am CT

Author: Xiaotong Li, PhD

Poster #/Location: 578/Board 70

Hyperlink: <https://meetinglibrary.asco.org/record/162778/abstract>

Title: Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTO trials

Date/Time: Monday, April 16 2018, 1pm-5:00pm CT

Author: Saranya Chumsri, MD

Poster #/Location: 577/Board 69

Hyperlink: <https://meetinglibrary.asco.org/record/162783/abstract>

### **Lymphoma Sub-typing (Lymphmark™)**

Title: Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST)

Date/Time: Monday, June 4, 2018, 8am-11:30am CT

Author: Grzegorz S. Nowakowski, MD

Poster #/Location: 7548/Board 185

Hyperlink: <https://meetinglibrary.asco.org/record/162322/abstract>

Title: Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Date/Time: Monday, June 4, 2018, 1pm-5:00pm CT

Author: Martin JS Dyer, PhD

Poster #/Location: 7547/Board 184

Hyperlink: <https://meetinglibrary.asco.org/record/162360/abstract>

Title: Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study

Date/Time: Monday, June 4, 2018, 8am-11:30am CT

Author: Kana Miyazaki, MD, PhD

Poster #/Location: 7561/Board 198

Hyperlink: <https://meetinglibrary.asco.org/record/162387/abstract>

### **Breast Cancer (Prosigna®-PAM50)**

Title: SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Date/Time: Saturday, June 2, 2018, 8am-11:30am CT

Author: Patricia Villagrasa, PhD

Poster #/Location: TPS1101/Board 181b

Hyperlink: <https://meetinglibrary.asco.org/record/165311/abstract>

Title: PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.

Date/Time: Saturday, June 2, 2018, 1pm-5:00pm CT

Author: Tomás Pascual, MD

Poster #/Location: 1025/Board 106

Hyperlink: <https://meetinglibrary.asco.org/record/161762/abstract>

Title: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Date/Time: Saturday, June 2, 2018, 8am-11:30am CT

Author: Aleix Prat, MD, PhD

Poster #/Location: 509/Board 1

Hyperlink: <https://meetinglibrary.asco.org/record/161696/abstract>

Title: Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial

Date/Time: Saturday, June 2, 2018, 8am-11:30am CT

Author: Sandra M. Swain, MD

Poster #/Location: 580/Board 72

Hyperlink: <https://meetinglibrary.asco.org/record/162624/abstract>

Abstract #	Title	Hyperlink
578	Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide	<a href="https://meetinglibrary.asco.org/record/162778/abstract">https://meetinglibrary.asco.org/record/162778/abstract</a>
1533	Genomic profiling of tumors from patients with germline BRCA mutations	<a href="https://meetinglibrary.asco.org/record/163711/abstract">https://meetinglibrary.asco.org/record/163711/abstract</a>
577	Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials	<a href="https://meetinglibrary.asco.org/record/162783/abstract">https://meetinglibrary.asco.org/record/162783/abstract</a>
585	Immune profiling of BRCA-mutated breast cancers	<a href="https://meetinglibrary.asco.org/record/163391/abstract">https://meetinglibrary.asco.org/record/163391/abstract</a>
4509	Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)	<a href="https://meetinglibrary.asco.org/record/161707/abstract">https://meetinglibrary.asco.org/record/161707/abstract</a>
TPS1101	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer	<a href="https://meetinglibrary.asco.org/record/165311/abstract">https://meetinglibrary.asco.org/record/165311/abstract</a>
6059	Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC)	<a href="https://meetinglibrary.asco.org/record/163405/abstract">https://meetinglibrary.asco.org/record/163405/abstract</a>
2027	Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients	<a href="https://meetinglibrary.asco.org/record/164151/abstract">https://meetinglibrary.asco.org/record/164151/abstract</a>
6047	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)	<a href="https://meetinglibrary.asco.org/record/162474/abstract">https://meetinglibrary.asco.org/record/162474/abstract</a>
1022	First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses	<a href="https://meetinglibrary.asco.org/record/158537/abstract">https://meetinglibrary.asco.org/record/158537/abstract</a>
11536	Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC)	<a href="https://meetinglibrary.asco.org/record/162153/abstract">https://meetinglibrary.asco.org/record/162153/abstract</a>
6017	Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma	<a href="https://meetinglibrary.asco.org/record/161539/abstract">https://meetinglibrary.asco.org/record/161539/abstract</a>
1025	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial	<a href="http://www.abstractsonline.com/pp8/#!/4562/presentation/2737">http://www.abstractsonline.com/pp8/#!/4562/presentation/2737</a>
509	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials	<a href="https://meetinglibrary.asco.org/record/161696/abstract">https://meetinglibrary.asco.org/record/161696/abstract</a>
580	Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial	<a href="https://meetinglibrary.asco.org/record/162624/abstract">https://meetinglibrary.asco.org/record/162624/abstract</a>
9018	Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1	<a href="https://meetinglibrary.asco.org/record/160279/abstract">https://meetinglibrary.asco.org/record/160279/abstract</a>
9585	Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4	<a href="https://meetinglibrary.asco.org/record/163660/abstract">https://meetinglibrary.asco.org/record/163660/abstract</a>
5569	Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC)	<a href="https://meetinglibrary.asco.org/record/161743/abstract">https://meetinglibrary.asco.org/record/161743/abstract</a>
1012	Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data	<a href="https://meetinglibrary.asco.org/record/160551/abstract">https://meetinglibrary.asco.org/record/160551/abstract</a>
9559	Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFM): Implications for combination with immunotherapy	<a href="https://meetinglibrary.asco.org/record/163593/abstract">https://meetinglibrary.asco.org/record/163593/abstract</a>
9530	Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody	<a href="https://meetinglibrary.asco.org/record/163453/abstract">https://meetinglibrary.asco.org/record/163453/abstract</a>
7547	Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)	<a href="https://meetinglibrary.asco.org/record/162360/abstract">https://meetinglibrary.asco.org/record/162360/abstract</a>
12057	Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC)	<a href="https://meetinglibrary.asco.org/record/164519/abstract">https://meetinglibrary.asco.org/record/164519/abstract</a>
9580	Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma	<a href="https://meetinglibrary.asco.org/record/163527/abstract">https://meetinglibrary.asco.org/record/163527/abstract</a>
9576	Validation of a prognostic 53-immune-gene panel in stage II/III melanoma	<a href="https://meetinglibrary.asco.org/record/163447/abstract">https://meetinglibrary.asco.org/record/163447/abstract</a>
5583	A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer	<a href="https://meetinglibrary.asco.org/record/161604/abstract">https://meetinglibrary.asco.org/record/161604/abstract</a>
5585	Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer	<a href="https://meetinglibrary.asco.org/record/161683/abstract">https://meetinglibrary.asco.org/record/161683/abstract</a>

TPS2617	A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR $\gamma$ agonist to treat select solid tumors	<a href="https://meetinglibrary.asco.org/record/165349/abstract">https://meetinglibrary.asco.org/record/165349/abstract</a>
9574	Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial	<a href="https://meetinglibrary.asco.org/record/163696/abstract">https://meetinglibrary.asco.org/record/163696/abstract</a>
7561	Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study	<a href="https://meetinglibrary.asco.org/record/162387/abstract">https://meetinglibrary.asco.org/record/162387/abstract</a>
12072	A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma	<a href="https://meetinglibrary.asco.org/record/164866/abstract">https://meetinglibrary.asco.org/record/164866/abstract</a>
5566	Inhibition of the Wnt/ $\beta$ -catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer	<a href="https://meetinglibrary.asco.org/record/163525/abstract">https://meetinglibrary.asco.org/record/163525/abstract</a>
3089	Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy	<a href="https://meetinglibrary.asco.org/record/159180/abstract">https://meetinglibrary.asco.org/record/159180/abstract</a>
7548	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST)	<a href="https://meetinglibrary.asco.org/record/162322/abstract">https://meetinglibrary.asco.org/record/162322/abstract</a>
9541	Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma	<a href="https://meetinglibrary.asco.org/record/163701/abstract">https://meetinglibrary.asco.org/record/163701/abstract</a>
3076	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers	<a href="https://meetinglibrary.asco.org/record/159233/abstract">https://meetinglibrary.asco.org/record/159233/abstract</a>
507	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study	<a href="https://meetinglibrary.asco.org/record/160260/abstract">https://meetinglibrary.asco.org/record/160260/abstract</a>
e15139	Characterization of the colorectal cancer immune microenvironment using a novel high-plex protein analysis technology	<a href="https://meetinglibrary.asco.org/record/159318/abstract">https://meetinglibrary.asco.org/record/159318/abstract</a>
e24243	Gene expression signature development to decode breast cancer heterogeneity	<a href="https://meetinglibrary.asco.org/record/164473/abstract">https://meetinglibrary.asco.org/record/164473/abstract</a>
e17063	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors	<a href="https://meetinglibrary.asco.org/record/161398/abstract">https://meetinglibrary.asco.org/record/161398/abstract</a>
e18015	Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma	<a href="https://meetinglibrary.asco.org/record/165024/abstract">https://meetinglibrary.asco.org/record/165024/abstract</a>
e21610	Effect of combination immunotherapy on tumor growth, survival, and intratumoral immune infiltration in transgenic murine model of melanoma	<a href="https://meetinglibrary.asco.org/record/163694/abstract">https://meetinglibrary.asco.org/record/163694/abstract</a>
e16579	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC)	<a href="https://meetinglibrary.asco.org/record/160470/abstract">https://meetinglibrary.asco.org/record/160470/abstract</a>
e17072	Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer	<a href="https://meetinglibrary.asco.org/record/161350/abstract">https://meetinglibrary.asco.org/record/161350/abstract</a>
e16554	Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC)	<a href="https://meetinglibrary.asco.org/record/160603/abstract">https://meetinglibrary.asco.org/record/160603/abstract</a>
e21600	Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma	<a href="https://meetinglibrary.asco.org/record/163510/abstract">https://meetinglibrary.asco.org/record/163510/abstract</a>
e16024	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes	<a href="https://meetinglibrary.asco.org/record/164795/abstract">https://meetinglibrary.asco.org/record/164795/abstract</a>
e15593	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness	<a href="https://meetinglibrary.asco.org/record/158896/abstract">https://meetinglibrary.asco.org/record/158896/abstract</a>
e21578	T-cell biological aging in melanoma: Impact on immunotherapeutic discontinuation	<a href="https://meetinglibrary.asco.org/record/163497/abstract">https://meetinglibrary.asco.org/record/163497/abstract</a>
e15121	Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)	<a href="https://meetinglibrary.asco.org/record/159447/abstract">https://meetinglibrary.asco.org/record/159447/abstract</a>
e18017	Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma	<a href="https://meetinglibrary.asco.org/record/165021/abstract">https://meetinglibrary.asco.org/record/165021/abstract</a>
e12634	Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab	<a href="https://meetinglibrary.asco.org/record/162921/abstract">https://meetinglibrary.asco.org/record/162921/abstract</a>

#### About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,950 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit [www.nanostring.com](http://www.nanostring.com).

NanoString, NanoString Technologies, the NanoString logo, IO360, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. All third party trademarks are the property of their respective owners.

Contact:

**Doug Farrell**

Vice President, Investor Relations & Corporate Communications

[dfarrell@nanosttring.com](mailto:dfarrell@nanosttring.com)

Phone: 206-602-1768



Source: NanoString Technologies, Inc.